Clinical Trial Update: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating immunogenicity response after eribulin treatment in advanced/metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer Metastasis
• Neoplasm Breast

Drugs mentioned

• Eribulin (eribulin mesilate)

Snippet

Sponsor: Institut fuer Frauengesundheit | Conditions: Breast Cancer Female, Neoplasm, Breast | Phase 4 | Status: UNKNOWN